Gum graft for dental implants is a broad description. Before comparing materials or recovery stories, ask whether the proposed treatment aims to widen the band of keratinized mucosa, increase tissue thickness or change the position of the gum margin. These outcomes need different measurements.
The useful treatment question is what the graft is intended to improve at your particular implant. A photograph showing a gray edge does not establish that grafting is necessary, which graft to use or how completely a visible surface could be covered.
Separate width, thickness and recession
Keratinized mucosa is the tissue band that clinicians may measure around an implant. Its width, often abbreviated KMW, is different from the thickness of the tissue over the underlying structures. Mucosal recession describes the position of the tissue margin. More width does not automatically establish more coverage of an exposed component.
Ask the clinician to name the finding, describe its functional or appearance-related consequence and identify the baseline measurement. If cleaning is uncomfortable or difficult, explain the location. If the concern is an exposed surface or gray shadow, bring earlier photographs and use the visible-metal guide to describe the change without diagnosing it.
Graft names belong beside their intended endpoint
A free gingival graft, or FGG, transfers the patient's own tissue and is commonly studied for increasing keratinized mucosal width. A subepithelial connective tissue graft, often called SCTG, is also autogenous tissue, but studies may evaluate it primarily for volume or thickness. A collagen matrix is a substitute material whose product and intended task need to be specified.
These categories should not be treated as interchangeable. Ask whether a proposal involves a palatal donor site, what local aftercare is required and what alternative material would change. The term "collagen matrix" alone does not identify the same product or clinical endpoint across trials.
A width-focused trial included delayed grafting
Oh and colleagues' 2020 extended trial follow-up reported 48-month observations around implants that initially had limited keratinized mucosa. The FGG group maintained gains in width and reduced recession. Some control implants received grafting after the original 18-month period, forming a separate delayed-treatment group.
This published course illustrates why timing and group membership matter. The extension involved small groups, and not every control site remained untreated. It cannot prove that every implant with a narrow tissue band requires surgery or that postponement has the same consequences in every patient.
A five-year comparison separates tissue gain from satisfaction
A trial in a 2025 journal issue, first published online in 2024, randomized 30 patients with 44 posterior implants to collagen matrix or FGG treatment. Both groups gained keratinized mucosa and experienced shrinkage, while the FGG group retained greater width. Clinical parameters and marginal bone loss were similar between groups.
The study also collected early patient-reported outcomes and later satisfaction. Apart from greater early self-reported bleeding with FGG, it did not establish a general first-week comfort advantage for the matrix. A reduction in graft dimensions should therefore be distinguished from a complete treatment failure or an unhappy patient.
A thickness trial answers a different comparison
In a 2023 multicenter randomized trial, 88 patients received a volume-stable collagen matrix or SCTG at single implant sites. The primary endpoint concerned crestal mucosal thickness at 120 days. Seventy-nine patients attended the one-year follow-up.
The study did not demonstrate noninferiority of the matrix for that primary thickness outcome, although patient-reported pain favored the matrix. Failure to demonstrate noninferiority does not establish that the materials are identical. Nor should a comfort finding in this volume-focused trial replace the findings of a different width-focused study.
Connect the graft discussion to the restoration stage
Ask why grafting is being considered before implant placement, before the final crown or after an implant has been restored. The proposed sequence should identify the clinical goal and what must be reassessed before the next restorative decision.
The crown contour and cleaning access belong in the discussion too. A graft proposal should explain which part of the problem it addresses and what limitations remain. If inflammation or supporting bone loss is present, ask the dentist to explain its assessment separately rather than assume that a soft-tissue procedure resolves every finding.
For postoperative care, request instructions for both donor and recipient sites where relevant. Ask about permitted cleaning, food and wearing arrangements for any temporary restoration. Follow the treating team's review plan rather than adopting another patient's medication or healing timetable.
Costs should describe the actual graft and restorative sequence. Ask whether the estimate includes follow-up and any planned provisional adjustment. Neither the clinical trials nor a generic online price can supply that local treatment estimate.
Use one goal sheet for the consultation
This is an editorial record aid. It helps distinguish measurable treatment goals without recommending a graft or a surgical protocol.
| Goal or choice | Ask the team to record | Keep separate |
|---|---|---|
| Tissue endpoint | Width, thickness, margin position or a combination | The clinical measurement and the appearance goal |
| Material | Exact graft source or substitute and the reason for choosing it | Donor-site burden and expected tissue result |
| Timing | How the graft fits the implant and crown sequence | What can proceed now and what awaits reassessment |
| Review | Baseline record, follow-up date and criteria for judging change | Expected remodeling and findings needing earlier attention |
Bring reports of bleeding around the implant to the appointment. If the laboratory needs a record of the tissue contour, the emergence-profile transfer guide concerns that separate restorative task.
Sources and editorial provenance
Sources checked and article prepared November 18, 2026. The displayed November 14, 2026 at 13:40 Europe/Kyiv is an assigned editorial timestamp. Actual first production publication is recorded separately. The width studies are summarized from primary abstracts; the thickness trial's primary report was checked. Their materials, populations and endpoints remain separate. Published experiences belong to the cited investigators. This educational article does not replace individual treatment planning.
First production release recorded: . The date at the top is the editorial date.